BioSpace News Archive

According to Transparency Market Research’s latest report on the global collagen peptide and gelatin market for the historical period 2017–2018 and forecast period 2019–2027, increase in commercialization of novel collagen-based drug delivery systems and rise in social awareness about personal well-being are projected to drive the global collagen peptide and gelatin market.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global vaccine management solution market was valued at US$ 140 million in 2019.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global medical laser systems market is projected to grow at a steady pace, expanding at a CAGR of 8.5% during the forecast period 2021 to 2031, as per a study by Fact.MR.

Positive study results for MIV-818 and remetinostat. Design determined for the combination study with MIV-818.

BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, announced that it has been named one of the Top 10 Spine Device Companies and featured by MedTech Outlook, a leading print and digital magazine that provides details and insights regarding novel and high impact medical technologies.

Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company focused on the development of prescription therapeutics to address IgE-mediated food allergy, announced it has initiated the buildout of a new state-of-the-art manufacturing facility to support future production of its lead product candidate, ADP101.

PharmaCyte Biotech, Inc. today announced that it has entered into definitive agreements with institutional investors for the purchase and sale, in a registered direct offering priced at-the-marked under Nasdaq rules.

Visus Therapeutics Inc. announced it has entered into a worldwide exclusive licensing agreement with Cella Therapeutics to develop an array of investigational ophthalmic therapies to treat glaucoma and age-related macular degeneration, two of the leading causes of blindness globally.

Humacyte, Inc announced today the successful completion of its 13th Expanded Access Program (EAP) implant of its bioengineered blood vessel, the Human Acellular Vessel (HAV), in the U.S.

Oncology Pharma Inc. has finalized a Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.